John Libbey Eurotext

European Journal of Dermatology


Scalp psoriasis in a haemodialysis patient successfully treated with a half-dose of apremilast Volume 29, numéro 3, May-June 2019


  • Figure 1
1 Department of Dermatology, Teikyo University School of Medicine, Tokyo,
2 Department of Dermatology, Sanno Hospital, Tokyo,
3 Department of Dermatology, Jichi Medical University, Shimotsuke, Japan.

Psoriasis is a chronic inflammatory skin disease characterized by scaly erythema spreading over the body. Scalp psoriasis is often refractory to treatment and significantly impairs patients’ quality of life. While a variety of treatments are available for psoriasis, experience with these treatments for haemodialysis patients is fairly limited. Apremilast, an oral phosphodiesterase (PDE)-4 inhibitor, became available for the treatment of psoriasis in Japan in 2017, and there are a couple of reports [...]